Processing Your Payment

Please do not leave this page until complete. This can take a few moments.

September 20, 2022

Trevi reports promising results from completed drug trial for cough

PHOTO | CONTRIBUTED Trevi Therapeutics CEO Jennifer Good
By Liese Klein

New Haven’s Trevi Therapeutics announced positive results on Monday from the completed clinical trial of its flagship medication in patients with chronic cough caused by a serious lung ailment. 

Haduvio, Trevi’s oral, extended-release formulation of the synthetic opioid agonist-antagonist  nalbuphine, showed positive results from the full set of subjects in a Phase 2 clinical trial, Trevi reported. Patients who took the drug in the trial were adults with idiopathic pulmonary fibrosis (IPF), a serious disease that causes scar tissue to grow inside the lungs which impairs breathing and causes coughing.

Early promising results prompted Trevi to end enrollment in the trial early, in March, although patients already enrolled were allowed to complete the trial. The latest announcement about Haduvio’s results comes from the full set of subjects who took part.

Patients reported a 75.1% reduction in daytime cough frequency when taking Haduvio, according to a statement. Patients showed consistent reductions in cough frequency over 24 hours and during the daytime when compared to a placebo. 

Trevi President and CEO Jennifer Good said, “There are no approved therapies for chronic cough in these patients, and we are excited to continue our development in this indication and look forward to starting our next clinical trial for these patients in the first half of 2023.”

In June, Trevi reported positive results in a trial of Haduvio for the treatment of prurigo nodularis, a chronic inflammatory skin disease that causes intense itching.

Contact Liese Klein at lklein@newhavenbiz.com.

Sign up for Enews

Most Recent

Most Recent

0 Comments

Order a PDF